Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SC99 是一种口服有效选择性STAT3抑制剂,靶向 JAK2-STAT3 途径,抑制血小板活化和聚集,有抗骨髓瘤和抗血栓活性。它结合在 JAK2 的 ATP 结合袋中,抑制 JAK2 和 STAT3 的磷酸化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 639 | 现货 | ||
2 mg | ¥ 938 | 现货 | ||
5 mg | ¥ 1,570 | 现货 | ||
10 mg | ¥ 2,380 | 现货 | ||
25 mg | ¥ 3,930 | 现货 | ||
50 mg | ¥ 5,750 | 现货 | ||
100 mg | ¥ 7,290 | 现货 | ||
500 mg | ¥ 14,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,730 | 现货 |
产品描述 | SC99 is a selective inhibitor of JAK2-STAT3 activation. SC99 downregulates the expression of STAT3-modulated genes.SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities |
体外活性 | SC99 inhibited the phosphorylation of JAK2 and STAT3 in human platelets but had no effects on the phosphorylation of AKT, p65 or Src, all of which are involved in platelet activation.?SC99 inhibited human platelet aggregation induced by collagen and thrombin in a dose-dependent manner.?SC99 inhibited thrombin-induced P-selectin expression and fibrinogen binding to single platelets.?Moreover, SC99 inhibited platelet spreading on fibrinogen and clot retraction mediated by outside-in signaling.?SC99 inhibited platelet aggregation in mice but it did not significantly prolong the bleeding time.?SC99 inhibited platelet activation and aggregation as a STAT3 inhibitor.?This agent can be developed as a promising treatment for thrombotic disorders. |
分子量 | 336.15 |
分子式 | C15H8Cl2FN3O |
CAS No. | 882290-02-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 82 mg/mL (243.94 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9749 mL | 14.8743 mL | 29.7486 mL | 74.3716 mL |
5 mM | 0.595 mL | 2.9749 mL | 5.9497 mL | 14.8743 mL | |
10 mM | 0.2975 mL | 1.4874 mL | 2.9749 mL | 7.4372 mL | |
20 mM | 0.1487 mL | 0.7437 mL | 1.4874 mL | 3.7186 mL | |
50 mM | 0.0595 mL | 0.2975 mL | 0.595 mL | 1.4874 mL | |
100 mM | 0.0297 mL | 0.1487 mL | 0.2975 mL | 0.7437 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SC99 882290-02-0 Angiogenesis Apoptosis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK STAT orally ERK c-Src ATP-binding phosphorylation platelet AKT Janus kinase activation SC-99 anti-myeloma mTOR anti-thrombotic Inhibitor myeloma pocket multiple aggregation OPM2 SC 99 inhibit inhibitor